NEW YORK (GenomeWeb News) – Qiagen reported after the close of the market on Monday that its second-quarter revenues rose 61 percent and its adjusted net income, which excludes acquisition-related items, increased 57 percent year over year.
Qiagen also announced that it had settled litigation with Idaho Technology related to thermal cycling technology.
For the three-month period ended June 30, the firm generated revenues of $217.9 million compared to $135 million for the second quarter of 2007.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.